Kyntra Bio

Kyntra Bio, formerly known as FibroGen, is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and rare diseases. Following a strategic rebranding in early 2026, the company shifted its focus toward mid- and late-stage assets, including roxadustat, a first-in-class small molecule treatment for anemia. Its lead oncology program is FG-3246, an antibody-drug conjugate (ADC) targeting CD46, currently in Phase 2 development for metastatic castration-resistant prostate cancer. The company is also advancing a pipeline of novel checkpoint inhibitors and imaging agents, leveraging its legacy expertise in hypoxia biology and monoclonal antibodies. Kyntra Bio is headquartered in San Francisco and is publicly traded on the Nasdaq.